Beam Therapeutics Inc. Cash Flow Statement
BEAM / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Beam Therapeutics Inc. used $345M in operating cash flow and negative free cash flow of $360M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$80.0M | -$376.7M | -$132.5M | -$289.1M | -$370.6M | -$78.3M | -$78.3M |
| Depreciation & Amortization | $22.3M | $21.9M | $20.0M | $14.1M | $7.5M | $3.5M | $3.5M |
| Operating Cash Flow | -$345.1M | -$347.2M | -$149.2M | $22.5M | -$66.3M | -$72.0M | -$72.0M |
| Capital Expenditures | $14.9M | $8.9M | $33.7M | $49.0M | $46.8M | $12.5M | $12.5M |
| Free Cash Flow | -$360.0M | -$356.2M | -$182.9M | -$26.4M | -$113.1M | -$84.5M | -$84.5M |
| FCF Margin | -257.6% | -560.8% | -48.4% | -43.4% | -218.1% | -469561.1% | - |